Entrada Therapeutics Operating Income

Entrada Therapeutics (TRDA) currently reports a operating income of $-180M as of June 2026. That compares with $-96M in the prior-year period — down 83.6% year over year. Use the charts on this page to explore Entrada Therapeutics's operating income history and peer comparisons.

Entrada Therapeutics's operating income decreased from $-96M to $-180M — a 83.6% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Entrada Therapeutics reported $-180M in operating income as of June 2026. That compares with $-96M in the prior-year period — down 83.6% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current operating income of $-180M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Entrada Therapeutics, and consider following TRDA for alerts when major investors trade the stock.